Effects of Seed Cycling Capsules on Premenstrual Syndrome Symptoms and Menstrual Cycle Length

NCT07655466 | Completed

• 1 other identifier: #20756
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This virtual, single-arm clinical trial will evaluate the effects of Seed Cycling Capsules on symptoms associated with premenstrual syndrome (PMS) and menstrual cycle characteristics. Forty female participants aged 18 to 45 years will use the study products daily for two menstrual cycles. Participants will complete questionnaires at baseline, at the end of their period during Cycle 1, and at the end of their period during Cycle 2.

Conditions

Premenstrual Syndrome; Menstrual Symptoms

Keywords

Hormonal Imbalance; Menstrual Health

Outcome Measures

Primary Outcomes (8)

• Change in Menstrual Cramp Severity

  Self-reported severity of premenstrual and menstrual cramps assessed using study questionnaires and compared between Baseline, Cycle 1, and Cycle 2.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Bloating Severity

  Self-reported severity of abdominal bloating associated with the menstrual cycle assessed using study questionnaires.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Fatigue Severity

  Self-reported fatigue associated with the menstrual cycle assessed using study questionnaires.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Hormonal Acne Severity

  Self-reported severity and frequency of hormonal acne symptoms assessed using study questionnaires.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Mood Symptoms

  Self-reported mood-related symptoms including low mood, irritability, and anger associated with the menstrual cycle.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Sleep Quality

  Self-reported sleep quality and insomnia symptoms associated with the menstrual cycle.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Breast Tenderness Severity

  Self-reported breast tenderness associated with the menstrual cycle.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Change in Libido

  Self-reported sex drive and libido associated with the menstrual cycle.

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

Secondary Outcomes (3)

• Participant Assessment of Overall Menstrual Experience

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Participant Satisfaction With Seed Cycling Capsules

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

• Participant Perception of Product Effectiveness

  Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

Study Arms (1)

Seed Cycling Capsules

EXPERIMENTAL

Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles.

Dietary Supplement: Two Moons Seed Cycling Capsules

Interventions

Two Moons Seed Cycling Capsules DIETARY_SUPPLEMENT

Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. Participants will take two capsules with the first meal of the day according to the following schedule: Zest Capsules from Days 1-14 of the cycle, and Zen Capsules from Days 15-28 of the cycle. Participants will continue this schedule for two menstrual cycles regardless of when subsequent menstrual periods occur.

Seed Cycling Capsules

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Be female.
• Be 18-45 years of age.
• Have experienced at least five of the following symptoms during the last three menstrual cycles:
• Heavy flow Prolonged, shortened, or irregular periods Headaches or migraines Low mood Fatigue Bloating Premenstrual or menstrual cramps Breast tenderness Poor sleep Constipation or diarrhea Weight gain or fluctuations Irritability or anger Sick days or reduced social activity due to menstrual symptoms Hormonal acne
• Be generally healthy.
• Have a menstrual cycle length between 23 and 35 days.
• Track menstrual cycles and be able to predict period dates.
• Be willing to refrain from taking products, medications, or supplements targeting menstrual health during the study.

You may not qualify if:

• Use of hormonal contraception.
• Allergy to sesame.
• Chronic conditions that would interfere with study participation, including oncological and psychiatric disorders.
• Pregnant, breastfeeding, or trying to conceive.
• Unwillingness to follow the protocol.
• Menopause or menopausal symptoms.
• Recent or planned invasive medical procedures.
• History of substance abuse.
• Diabetes or other endocrine-related conditions.
• Current or planned participation in another research study.
• Use of hormone-modulating medications or therapies.
• Planned insertion or replacement of an IUD within 12 weeks.
• Diagnosis of endometriosis, polycystic ovary syndrome (PCOS), or adenomyosis.

Sponsors & Collaborators

• Superlune Inc. d/b/a Two Moons Health: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Premenstrual Syndrome

Condition Hierarchy (Ancestors)

Menstruation Disturbances; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 9, 2026
• First Posted: June 17, 2026
• Study Start: July 8, 2025
• Primary Completion: September 27, 2025
• Study Completion: September 27, 2025
• Last Updated: June 17, 2026

Record last verified: 2026-06

Locations

US (1)